Agomab Therapeutics
Antwerp, BE · 7 known investors
Agomab is a clinical-stage biopharmaceutical company developing disease-modifying therapies for fibro-inflammatory and fibrotic diseases with high unmet medical need. Its product candidates target established biological pathways using organ-restricted approaches to resolve fibro-inflammation and restore organ function.
BiotechHealthtechMedical Devices
Founders & leadership
TK
Tim KnotnerusChief Executive Officer
Investors · 7
Competitors · 4
by search overlapAdimab12 shared keywordsAdimab operates a yeast-based antibody discovery and engineering platform that produces fully human antibodies, heavy-chain antibodies, and multispecifics (including T-cell engagers) for biopharma partners. It offers services from antigen acquisition through preclinical lead generation, including AI-guided protein engineering, and works with partners through discovery, platform licensing, and technology-module collaboration models.
Bioworld8 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
EquityZen6 shared keywordsEquityZen operates an online marketplace that gives accredited individual investors access to shares in late-stage private companies through secondary market transactions. Now part of Morgan Stanley, the platform provides private market data, offering documents, and guided investment processes for buying and selling pre-IPO equity.
Robinhood6 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies competing with Agomab Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Agomab Therapeutics do?
- Agomab is a clinical-stage biopharmaceutical company developing disease-modifying therapies for fibro-inflammatory and fibrotic diseases with high unmet medical need. Its product candidates target established biological pathways using organ-restricted approaches to resolve fibro-inflammation and restore organ function.
- Who are Agomab Therapeutics's investors?
- Agomab Therapeutics's investors include EQT Life Sciences, AdBio partners, Andera Partners, Asabys Partners, Canaan Partners, Pontifax Venture Capital, V-Bio Ventures.
- Where is Agomab Therapeutics headquartered?
- Agomab Therapeutics is headquartered in Antwerp, BE.